Do Exophytic and Endophytic Patterns in Borderline Ovarian Tumors Have Different Prognostic Implications? A Large Multicentric Experience.
BOT
borderline ovarian tumor
endophytic pattern
exophytic pattern
tumor growth
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 May 2023
18 May 2023
Historique:
received:
13
04
2023
revised:
12
05
2023
accepted:
16
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Borderline ovarian tumor (BOT) accounts for 15-20% of all epithelial ovarian tumors. Concerns have arisen about the clinical and prognostic implications of BOT with exophytic growth patterns. We retrospectively reviewed all cases of BOT patients surgically treated from 2015 to 2020. Patients were divided into an endophytic pattern (with intracystic tumor growth and intact ovarian capsule) and an exophytic pattern (with tumor growth outside the ovarian capsule) group. Among the 254 patients recruited, 229 met the inclusion criteria, and of these, 169 (73.8%) belonged to the endophytic group. The endophytic group showed more commonly an early FIGO stage than the exophytic group (100.0% vs. 66.7%,
Identifiants
pubmed: 37240649
pii: jcm12103544
doi: 10.3390/jcm12103544
pmc: PMC10219359
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Surg Pathol. 2003 Jun;27(6):725-36
pubmed: 12766576
Ann Oncol. 2003 Apr;14(4):592-8
pubmed: 12649107
Tumour Biol. 2017 May;39(5):1010428317706230
pubmed: 28488545
Int J Cancer. 2008 Oct 15;123(8):1897-901
pubmed: 18661518
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8
pubmed: 25341581
Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153
pubmed: 34629493
J Natl Cancer Inst. 2001 Aug 1;93(15):1147-52
pubmed: 11481386
Tumour Biol. 2017 Oct;39(10):1010428317733984
pubmed: 28992761
J Pathol. 2014 Jan;232(1):16-22
pubmed: 24307542
Virchows Arch. 2017 Feb;470(2):125-142
pubmed: 28025670
Virchows Arch. 2021 May;478(5):885-891
pubmed: 33009577
Ultrasound Obstet Gynecol. 2000 Oct;16(5):500-5
pubmed: 11169340
Gynecol Oncol. 2014 Jun;133(3):401-4
pubmed: 24878391
J Clin Oncol. 2001 May 15;19(10):2658-64
pubmed: 11352957
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Int J Gynecol Pathol. 2010 Mar;29(2):108-12
pubmed: 20173495
Oncologist. 2012;17(12):1515-33
pubmed: 23024155
Gynecol Oncol. 2010 Nov;119(2):270-3
pubmed: 20719369
Lancet Oncol. 2012 Mar;13(3):e103-15
pubmed: 22381933
Mod Pathol. 2005 Feb;18 Suppl 2:S33-50
pubmed: 15761465
Cancer Res. 1998 Jun 1;58(11):2328-30
pubmed: 9622067
Oncology (Williston Park). 2003 Nov;17(11):1563-7; discussion 1567-70, 1575
pubmed: 14682108
Ultrasound Obstet Gynecol. 2017 Dec;50(6):788-799
pubmed: 28101917
Am J Surg Pathol. 1992 Jun;16(6):577-83
pubmed: 1599036
Gynecol Oncol. 2010 Apr;117(1):1-3
pubmed: 20298906
Int J Gynecol Pathol. 1982;1(1):3-16
pubmed: 7184889
Jpn J Radiol. 2014 Sep;32(9):552-5
pubmed: 24838832
Surg Oncol. 2012 Sep;21(3):178-84
pubmed: 22418038
Ann Surg Oncol. 2021 Jul;28(7):3597-3604
pubmed: 33140251
Hum Pathol. 2004 Aug;35(8):910-7
pubmed: 15297959
Anticancer Res. 2014 Nov;34(11):6725-30
pubmed: 25368281
Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii
pubmed: 12959182
Acta Obstet Gynecol Scand. 2007;86(4):484-90
pubmed: 17486473
Am J Surg Pathol. 2000 Nov;24(11):1447-64
pubmed: 11075847
BMC Cancer. 2013 Oct 18;13:483
pubmed: 24139521
Biomed Res Int. 2014;2014:803598
pubmed: 25431767
Fertil Steril. 2001 Jan;75(1):92-6
pubmed: 11163822
J Clin Ultrasound. 2015 Nov-Dec;43(9):573-7
pubmed: 25706035
Hum Pathol. 2000 May;31(5):539-57
pubmed: 10836293
Am J Obstet Gynecol. 2013 Jul;209(1):58.e1-8
pubmed: 23583213
Am J Surg Pathol. 2019 Nov;43(11):1462-1472
pubmed: 31343420
Hum Pathol. 2004 Aug;35(8):949-60
pubmed: 15297962